1 Comprehensive Pneumology Center, University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany.
2 Institute of Molecular Immunology, Helmholtz Zentrum München, Munich, Germany.
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1230-41. doi: 10.1164/rccm.201506-1122OC.
Patients with chronic obstructive pulmonary disease (COPD) and in particular smokers are more susceptible to respiratory infections contributing to acute exacerbations of disease. The immunoproteasome is a specialized type of proteasome destined to improve major histocompatibility complex (MHC) class I-mediated antigen presentation for the resolution of intracellular infections.
To characterize immunoproteasome function in COPD and its regulation by cigarette smoke.
Immunoproteasome expression and activity were determined in bronchoalveolar lavage (BAL) and lungs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigarette smoke-exposed mice. Smoke-mediated alterations of immunoproteasome activity and MHC I surface expression were analyzed in human blood-derived macrophages. Immunoproteasome-specific MHC I antigen presentation was evaluated in spleen and lung immune cells that had been smoke-exposed in vitro or in vivo.
Immunoproteasome and MHC I mRNA expression was reduced in BAL cells of patients with COPD and in isolated alveolar macrophages of patients with COPD or IPF. Exposure of immune cells to cigarette smoke extract in vitro reduced immunoproteasome activity and impaired immunoproteasome-specific MHC I antigen presentation. In vivo, acute cigarette smoke exposure dynamically regulated immunoproteasome function and MHC I antigen presentation in mouse BAL cells. End-stage COPD lungs showed markedly impaired immunoproteasome activities.
We here show that the activity of the immunoproteasome is impaired by cigarette smoke resulting in reduced MHC I antigen presentation. Regulation of immunoproteasome function by cigarette smoke may thus alter adaptive immune responses and add to prolonged infections and exacerbations in COPD and IPF.
慢性阻塞性肺疾病(COPD)患者,尤其是吸烟者,更容易受到导致疾病急性加重的呼吸道感染。免疫蛋白酶体是一种专门类型的蛋白酶体,旨在改善主要组织相容性复合体(MHC)I 类介导的抗原呈递,以解决细胞内感染。
描述 COPD 中的免疫蛋白酶体功能及其受香烟烟雾的调节。
在支气管肺泡灌洗液(BAL)和人类供体以及 COPD 或特发性肺纤维化(IPF)患者的肺中,以及在暴露于香烟烟雾的小鼠中,确定免疫蛋白酶体的表达和活性。分析人源性巨噬细胞中免疫蛋白酶体活性和 MHC I 表面表达的香烟烟雾调节作用。在体外或体内暴露于烟雾的脾和肺免疫细胞中,评估免疫蛋白酶体特异性 MHC I 抗原呈递。
COPD 患者的 BAL 细胞和 COPD 或 IPF 患者分离的肺泡巨噬细胞中的免疫蛋白酶体和 MHC I mRNA 表达降低。体外将免疫细胞暴露于香烟烟雾提取物中会降低免疫蛋白酶体活性并损害免疫蛋白酶体特异性 MHC I 抗原呈递。在体内,急性香烟烟雾暴露动态调节小鼠 BAL 细胞中的免疫蛋白酶体功能和 MHC I 抗原呈递。终末期 COPD 肺显示出明显受损的免疫蛋白酶体活性。
我们在此表明,香烟烟雾会损害免疫蛋白酶体的活性,从而导致 MHC I 抗原呈递减少。香烟烟雾对免疫蛋白酶体功能的调节可能会改变适应性免疫反应,并导致 COPD 和 IPF 中感染和加重的持续时间延长。